These data verify that interrupting the TRIB3/AKT1 interaction reduces breast cancer stemness and exerts antitumor efficacy by promoting FOXO1 phosphorylation, ubiquitination, and degradation, which suppresses SOX2 expression (Fig. 8g). This evidence concerns the gene TRIB3 and breast cancer.